Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy
Authors
Keywords
-
Journal
Canadian Journal of Gastroenterology and Hepatology
Volume 2018, Issue -, Pages 1-11
Publisher
Hindawi Limited
Online
2018-11-06
DOI
10.1155/2018/9450754
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LBA-004Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer
- (2018) J Bendell et al. ANNALS OF ONCOLOGY
- O-027BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer
- (2018) E Van Cutsem et al. ANNALS OF ONCOLOGY
- Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society
- (2018) Andrew M. D. Wolf et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis
- (2018) Els Wieten et al. GUT
- Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer–Specific Mortality in Patients With Stage II or III Colorectal Cancer
- (2018) Peer Wille-Jørgensen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Reply to R. Obeid et al
- (2018) Theodore M. Brasky et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
- (2018) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
- (2017) Julian Walter Holch et al. EUROPEAN JOURNAL OF CANCER
- Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis
- (2017) Douglas A. Corley et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer
- (2017) Sabine Tejpar et al. JAMA Oncology
- Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer
- (2017) Fausto Petrelli et al. JAMA Oncology
- Immunotherapy for Colorectal Cancer
- (2017) Patrick Boland et al. Cancers
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- ExtendedRASGene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
- (2016) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- Surveillance after curative treatment for colorectal cancer
- (2016) Eric P. van der Stok et al. Nature Reviews Clinical Oncology
- Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy
- (2016) Alessandro Ottaiano et al. ONCOLOGY
- Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
- (2016) E. J. Brea et al. Cancer Immunology Research
- Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)
- (2015) T. Aparicio et al. ANNALS OF ONCOLOGY
- Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
- (2015) A Rowland et al. BRITISH JOURNAL OF CANCER
- Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
- (2015) M. Peeters et al. CLINICAL CANCER RESEARCH
- The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4
- (2015) Marcela Crosara Teixeira et al. Clinical Colorectal Cancer
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
- (2015) S.Y. Brulé et al. EUROPEAN JOURNAL OF CANCER
- KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers
- (2015) Kyung Ha Lee et al. JOURNAL OF SURGICAL ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
- (2014) M. J. Sorich et al. ANNALS OF ONCOLOGY
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
- (2014) J. Y. Douillard et al. ANNALS OF ONCOLOGY
- Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
- (2014) E. Missiaglia et al. ANNALS OF ONCOLOGY
- Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†
- (2014) L. Decoster et al. ANNALS OF ONCOLOGY
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes
- (2014) Alex Rafacho et al. JOURNAL OF ENDOCRINOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
- (2013) David Cunningham et al. LANCET ONCOLOGY
- Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials
- (2013) H. I. Hurwitz et al. ONCOLOGIST
- Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review
- (2012) Cheng-Bo Han et al. CANCER INVESTIGATION
- The Effect of Diabetes on Oxaliplatin-Induced Peripheral Neuropathy
- (2012) Augusta N. Uwah et al. Clinical Colorectal Cancer
- The relationship between tumour site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer
- (2012) A. G. M. T. Powell et al. Colorectal Disease
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- How to identify older patients with cancer who should benefit from comprehensive geriatric assessment?
- (2012) S. Luce et al. Journal of Geriatric Oncology
- Is Diabetes Mellitus an Independent Risk Factor for Colon Cancer and Rectal Cancer?
- (2011) Hiroki Yuhara et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer
- (2011) P. Cen et al. ANNALS OF ONCOLOGY
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival
- (2011) Frank Benedix et al. DISEASES OF THE COLON & RECTUM
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
- (2011) Matthew T Seymour et al. LANCET
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Screening older cancer patients for a Comprehensive Geriatric Assessment: A comparison of three instruments
- (2011) Cynthia Owusu et al. Journal of Geriatric Oncology
- Older adults and cancer treatment
- (2010) Barbara Given et al. CANCER
- Colorectal Cancer Incidence Trends in the United States and United Kingdom: Evidence of Right- to Left-Sided Biological Gradients with Implications for Screening
- (2010) R. Meza et al. CANCER RESEARCH
- Microsatellite Instability in Colorectal Cancer
- (2010) C. Richard Boland et al. GASTROENTEROLOGY
- Clinical Relevance of KRAS in Human Cancers
- (2010) Sylwia Jančík et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies
- (2009) R. K. Ramanathan et al. ANNALS OF ONCOLOGY
- Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer
- (2009) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study
- (2008) Eric François et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer
- (2008) Hendrik-Tobias Arkenau et al. Clinical Colorectal Cancer
- The changing prevalence of comorbidity across the age spectrum
- (2008) Jay F. Piccirillo et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study
- (2008) Javier Sastre et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now